Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds

Fig. 4

Effect of MEK162/BKM120 combination and BIBW2997/ARQ197 combination therapy on cell viability. H1975 (A), H460 (B), and A549 (C) cells were treated with 1 μM MEK162/5 μM BKM120 combination and 1 µM BIBW2992 (EGFR inhibitor)/2 µM ARQ 197 (MET inhibitor) combination for 48 h. Control cells were treated with 0.05% DMSO. Cell viability was evaluated by MTT assay. Data are percentages of viable cells compared with the controls and are represented as means ± SD from three independent experiments. *P < 0.05 vs. control (0.05% DMSO); #P < 0.05 vs. BKM120 + MEK162; ▲P < 0.05 vs. H1975; &P < 0.05 vs. H460

Back to article page